CGTN
8.2.2021 17:39:08 CET | Business Wire | Press release
Chinese President Xi Jinping has sent New Year's greetings to Chinese people of all ethnic groups, wishing happiness and good fortune for the people and prosperity for the nation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210208005631/en/
President Xi, also general secretary of the Communist Party of China Central Committee, extended the greetings during an inspection trip in southwest China's Guizhou Province prior to the Chinese New Year, which falls on February 12 this year.
"I'd like to extend Spring Festival blessings to people of all ethnic groups across the country. I wish everyone good health, happiness for their families, successful careers, and an auspicious Year of the Ox. I also wish our great motherland, with its beautiful mountains and rivers, much prosperity," Xi said.
During his trip, President Xi visited places including the city of Bijie and the provincial capital Guiyang, as well as a village, a residential community and a supermarket, from Wednesday to Friday.
His agenda also included a meeting with project leaders and core scientists of the Five-hundred-meter Aperture Spherical Radio Telescope (FAST) project in Guizhou. The FAST, held to be the world's most sensitive radio telescope, started operation on January 11, 2020.
On Friday's meet with scientists, President Xi called for a greater focus on scientific innovation and making it a driving force for China's development.
President Xi also spoke highly of the achievements made over the past year in Guizhou Province, as he heard a work report by the Guizhou Provincial CPC Committee and the provincial government on Friday.
He pointed out innovative development is an inevitable prerequisite of fostering China's new development paradigms and urged efforts to accelerate the integration of big data and the real economy and foster strategic merging industries.
More should be done to stimulate consumption demand and develop new consumption models, so as to unleash the consumption potential to the full, Xi said.
He demanded an effective transition from consolidating poverty alleviation achievements to promoting rural vitalization.
President Xi also expressed his great confidence in the future of the region, and wished it could make new achievements in the construction of ecological civilization.
A path of high-quality development that prioritizes ecology and highlights green development should be stuck, he added, adding that achieving common prosperity is one of the most important tasks of socialist modernization; and the government should support ethnic minorities in nurturing competitive industries and prospering their cultures.
He pointed out several aspects the government should work on to bring people benefits, including education, housing, employment, diseases prevention and control system as well as safe production.
Xi also stressed that the Red Army spent the longest time in Guizhou during the Long March, leaving behind precious spiritual treasures. And the Zunyi Conference, held in Zunyi City, is a crucial turning point in the Party's history.
The meeting focused on rectifying errors and established the correct leadership of the new Central Committee, as represented by Mao Zedong, Xi said, making it still matter today.
Original article：here .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210208005631/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom